Gliknik wins $1.5M contract from National Cancer Institute

Baltimore biopharmaceutical firm gets investment to prepare for clinical trials

October 03, 2011|By Gus G. Sentementes, The Baltimore Sun

Gliknik Inc., a biopharmaceutical company based at the University of Maryland's BioPark in downtown Baltimore, said Monday it had won a $1.5 million contract from the National Cancer Institute to continue development of its cancer-fighting technology.

The grant places the company on a path that could lead to clinical trials in two years, said David S. Block, Gliknik's chief executive.

Since its formation in 2007, Gliknik has raised $10 million from investors, largely with the help of Maryland's biotechnology tax credit. The company also has attracted $2.5 million in nonequity financing from government sources, including the grant from the National Cancer Institute.

    Baltimore Sun Articles
    Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.